- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05713136
Programa Nacional Australiano de Pruebas de VHC en el Punto de Atención - Conjunto de Datos Mínimo de Pruebas de Anticuerpos VHC
El Programa Nacional Australiano de Pruebas de VHC en el Punto de Atención: Un Estudio de Cohorte Observacional para Evaluar el Uso de Pruebas de Hepatitis C en el Punto de Atención con Punción Dactilar para Mejorar el Diagnóstico y el Tratamiento de la Infección por VHC - Conjunto de Datos Mínimo de Pruebas de Anticuerpos VHC
The goal of this observational study is to learn if offering a point-of-care screening test for exposure to the Hepatitis C virus, before providing a diagnostic test for Hepatitis C infection can increase testing, diagnosis and treatment in Adults. Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of Hepatitis C viral infection. The main question it aims to answer is:
What proportion of the participants that have been diagnosed with HCV infection have started treatment when their records are reviewed 12 weeks after diagnosis?
Participants will have one in-person visit where they will provide informed consent and receive a finger-prick rapid result test for Hepatitis C infection. Participants with no previous Hepatitis C infection will have a screening test to see if they have an immune reaction to Hepatitis C. Participants who know they have been infected with Hepatitis C in the past, and all participants with a positive screening test result will then be given a Hepatitis C diagnostic test at this visit.
No treatment is provided as a part of this study, participants who are diagnosed with Hepatitis C infection will be referred to testing locations standard of care for any additional clinical assessments and treatment initiation. A review of the participant's records will be made 12 weeks after their Hepatitis C result and their treatment data are gathered.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Stephanie Davey, BSc
- Número de teléfono: +61293481404
- Correo electrónico: sdavey@kirby.unsw.edu.au
Copia de seguridad de contactos de estudio
- Nombre: David Silk, BSc
- Número de teléfono: +61293850900
- Correo electrónico: dsilk@kirby.unsw.edu.au
Ubicaciones de estudio
-
-
Australian Capital Territory
-
Canberra, Australian Capital Territory, Australia
- Aún no reclutando
- ACT Justice Health
-
Contacto:
- Alex Misev
-
Investigador principal:
- Alex Misev, Dr
-
-
New South Wales
-
Sydney, New South Wales, Australia
- Reclutamiento
- Justice Health and Forensic Mental Health Network
-
Contacto:
- Tracey Brown
-
-
Queensland
-
Bowen Hills, Queensland, Australia, 4006
- Activo, no reclutando
- Queensland Injectors Health Network Ltd
-
Brisbane, Queensland, Australia
- Reclutamiento
- West Moreton Hospital and Health Service
-
Contacto:
- Chris Wallis
- Número de teléfono: (07) 3810 1111
- Correo electrónico: christopher.wallis@health.qld.gov.au
-
Cairns, Queensland, Australia
- Reclutamiento
- Lotus Glen Correctional Centre
-
Contacto:
- Kerry Williamson
- Número de teléfono: (07) 4093 3911
- Correo electrónico: Kerry.Williamson@Corrections.qld.gov.au
-
Townsville, Queensland, Australia, 4810
- Aún no reclutando
- Townsville Correctional Centre
-
Contacto:
- John Morey
-
Woodford, Queensland, Australia
- Reclutamiento
- Woodford Correctional Centre
-
Contacto:
- Lyn Cadman
- Número de teléfono: (07) 5422 5200
- Correo electrónico: lyn.cadman@health.qld.gov.au
-
-
South Australia
-
Adelaide, South Australia, Australia
- Aún no reclutando
- South Australian Prison Health Service
-
Contacto:
- Tom Turnbull
-
Investigador principal:
- Tom Turnbull
-
Hackney, South Australia, Australia, 5069
- Aún no reclutando
- Hepatitis South Australia
-
Contacto:
- Lisa Carter
-
-
Tasmania
-
Hobart, Tasmania, Australia
- Aún no reclutando
- Tasmanian Prison Service
-
Contacto:
- Deborah Siddell
-
Investigador principal:
- Meredith Stronach
-
-
Victoria
-
Melbourne, Victoria, Australia
- Reclutamiento
- St Vincent's Hospital (Melbourne)
-
Contacto:
- Alex Thompson
-
Investigador principal:
- Alex Thompson, Prof
-
-
Western Australia
-
Beechina, Western Australia, Australia, 6558
- Reclutamiento
- Acacia Prison
-
Contacto:
- Tahlia Kinnane
- Número de teléfono: (08) 9573 3300
- Correo electrónico: tahlia.kinnane@serco-ap.com
-
Perth, Western Australia, Australia, 6000
- Aún no reclutando
- WA Department of Justice
-
Contacto:
- Holly Beasley
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Participants will be included from settings that provide services to people with a risk factor for the acquisition of HCV infection, including drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, homelessness services, and other appropriate settings nationally. It is anticipated that approximately 40,000 participants will be screened for HCV infection using point-of-care HCV testing.
Descripción
Inclusion Criteria:
- Provide informed consent
- ≥ 18 years of age.
Exclusion Criteria:
- Is unable or unwilling to provide informed consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
People at risk of HCV acquisition
Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing |
Participants will be offered finger-stick point-of-care testing for HCV |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing.
Periodo de tiempo: 12 weeks from enrolment
|
HCV treatment |
12 weeks from enrolment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To evaluate the proportion of people who accept point-of-care testing among those offered testing.
Periodo de tiempo: Recruitment phase
|
Accepting testing |
Recruitment phase
|
|
To evaluate the prevalence of current HCV infection (HCV RNA quantifiable) among people tested.
Periodo de tiempo: Recruitment phase
|
Prevalence |
Recruitment phase
|
|
To evaluate the HCV antibody prevalence among people tested.
Periodo de tiempo: Recruitment phase
|
Prevalence |
Recruitment phase
|
|
To evaluate the time to treatment uptake among people receiving point-of-care HCV antibody testing with reflex HCV RNA testing in those who are HCV antibody detectable who received HCV treatment;
Periodo de tiempo: 52 weeks
|
Time to treatment |
52 weeks
|
|
To evaluate the proportion of HCV RNA positive participants who initiate HCV treatment at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing.
Periodo de tiempo: 52 weeks
|
Initiation of treatment |
52 weeks
|
|
To evaluate the proportion of participants who complete HCV direct-acting antiviral (DAA) treatment following point-of-care HCV antibody testing with reflex HCV RNA testing in those who are HCV antibody detectable who received HCV treatment;
Periodo de tiempo: 52 weeks
|
Completion of treatment |
52 weeks
|
|
To evaluate the proportion of participants who achieve an SVR following point-of-care HCV antibody testing with reflex HCV RNA testing in those who are HCV antibody detectable who received HCV treatment
Periodo de tiempo: 52 weeks
|
SVR |
52 weeks
|
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing.
Periodo de tiempo: 52 weeks
|
HCV negative |
52 weeks
|
|
To evaluate the cost of point-of-care HCV antibody testing prior to reflex HCV RNA testing compared to direct point-of-care HCV RNA testing and standard of care.
Periodo de tiempo: 52 weeks
|
Cost-effectiveness |
52 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- VHCRP2203
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .